Skip to content

The effect of gentamicin and methylprednisolon on vertigo.

The comparison of the effect intra tympanic methylprednisolon injection and intra tympanic gentamicin injection in control vertigo in patients with unilateral meniere's disease.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015041021582N1
Enrollment
20
Registered
2015-05-31
Start date
2014-11-29
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere,s disease. Meniere,s disease

Interventions

Intervention 1: intervention group 1- gentamicin with dose 27.6 mg once via intra tympanic injection. Intervention 2: intervention group 2- methyl perednosolone with dose 62.5 mg weekly intra tympani
Treatment - Drugs
intervention group 1- gentamicin with dose 27.6 mg once via intra tympanic injection
intervention group 2- methyl perednosolone with dose 62.5 mg weekly intra tympanic injection in three times

Sponsors

Deputy for research of Avaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with unilateral meniere's disease; Exclusion criteria: patients with bilateral meniere's disease; patients whose involved ear is the only hearing ear; not suffering from central nervous system disease; dissatisfaction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Vertigo. Timepoint: before treatment and 3 months later. Method of measurement: Questennaire.

Secondary

MeasureTime frame
Tinnitus. Timepoint: before treatment and 3 month later. Method of measurement: Questennaire.;Hearing loss. Timepoint: before treatment and 3 month later. Method of measurement: audiometry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArmin Arad

Ahvaz University of Medical Sciences

Aramesh302@Yahoo.com+98 613367543

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026